Selective delivery of therapeutic single strand antimiRs by aptamer-based conjugates

Journal of Controlled Release

Volumn 210, Issue , 2015, Pages 147-159

  Catuogno, Silvia ^a   Rienzo, Anna ^a   Di Vito, Aldo ^a   Esposito, Carla Lucia ^a   De Franciscis, Vittorio ^a  

^a CNR   (Italy)

Author keywords

AntimiR; Aptamer; Cancer; Targeted delivery; Therapy

Indexed keywords

AMINO ACIDS; CELLS; CYTOLOGY; DISEASES; ENZYMES; TUMORS;

ANTIMIR; APTAMERS; CANCER; TARGETED DELIVERY; THERAPY;

RNA;

APTAMER; DRUG CARRIER; MICRORNA 222; PROTEIN TYROSINE KINASE; TEMOZOLOMIDE; 2',5' OLIGOADENYLATE SYNTHETASE; AXL RECEPTOR TYROSINE KINASE; INTERLEUKIN 6; INTERLEUKIN 8; INTERLEUKIN-6, MOUSE; MICRORNA; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONJUGATE; CONTROLLED STUDY; DRUG DESIGN; DRUG SELECTIVITY; GENE DELIVERY SYSTEM; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TARGET CELL; TUMOR CELL; TUMOR SUPPRESSOR GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; GENETICS; LIVER; METABOLISM; NEOPLASMS; NUDE MOUSE; PATHOLOGY; SPLEEN; TUMOR CELL LINE; TUMOR VOLUME;

2',5'-OLIGOADENYLATE SYNTHETASE; ANIMALS; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; LIVER; MICE, NUDE; MICRORNAS; NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SPLEEN; TUMOR BURDEN;

EID: 84930681996     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.05.276     Document Type: Article

References (41)

1. G. Meister, M. Landthaler, A. Patkaniowska, Y. Dorsett, G. Teng, and T. Tuschl Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs Mol. Cell 15 2004 185 197
2. D.P. Bartel MicroRNAs: target recognition and regulatory functions Cell 136 2009 215 233
3. M.V. Iorio, and C.M. Croce Causes and consequences of microRNA dysregulation Cancer J. 18 2012 215 222
4. B.D. Adams, A.L. Kasinski, and F.J. Slack Aberrant regulation and function of microRNAs in cancer Curr. Biol. 24 2014 R762 R776
5. A.L. Kasinski, and F.J. Slack MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy Nat. Rev. Cancer 11 2011 849 864
6. J. Stenvang, A. Petri, M. Lindow, S. Obad, and S. Kauppinen Inhibition of microRNA function by antimiR oligonucleotides Silence 3 2012 1
7. M. Kortylewski, and S. Nechaev How to train your dragon: targeted delivery of microRNA to cancer cells in vivo Mol. Ther. 22 2014 1070 1071
8. B.R. Meade, K. Gogoi, A.S. Hamil, C. Palm-Apergi, A. van den Berg, J.C. Hagopian, A.D. Springer, A. Eguchi, A.D. Kacsinta, C.F. Dowdy, A. Presente, P. Lönn, M. Kaulich, N. Yoshioka, E. Gros, X.S. Cui, and S.F. Dowdy Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications Nat. Biotechnol. 32 2014 1256 1261
9. J.K. Kim, K.J. Choi, M. Lee, M.H. Jo, and S. Kim Molecular imaging of a cancer-targeting theranostics probe using a nucleolin aptamer- and microRNA-221 molecular beacon-conjugated nanoparticle Biomaterials 33 2012 207 217
10. C.J. Cheng, W.M. Saltzman, and F.J. Slack Canonical and non-canonical barriers facing antimiR cancer therapeutics Curr. Med. Chem. 20 2013 3582 3593
11. F. Sicard, M. Gayral, H. Lulka, L. Buscail, and P. Cordelier Targeting miR-21 for the therapy of pancreatic cancer Mol. Ther. 21 2013 986 994
12. M. Pofahl, J. Wengel, and G. Mayer Multifunctional nucleic acids for tumor cell treatment Nucleic Acid Ther. 24 2014 171 177
13. C.J. Cheng, R. Bahal, I.A. Babar, Z. Pincus, F. Barrera, C. Liu, A. Svoronos, D.T. Braddock, P.M. Glazer, D.M. Engelman, W.M. Saltzman, and F.J. Slack MicroRNA silencing for cancer therapy targeted to the tumour microenvironment Nature 518 2014 107 110
14. J. Zhou, and J.J. Rossi Cell-type-specific, aptamer-functionalized agents for targeted disease therapy Mol. Ther. Nucleic Acids 3 2014 e169
15. L. Cerchia, and V. de Franciscis Targeting cancer cells with nucleic acid aptamers Trends Biotechnol. 28 2010 517 525
16. J. Zhou, P. Swiderski, H. Li, J. Zhang, C.P. Neff, R. Akkina, and J.J. Rossi Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells Nucleic Acids Res. 37 2009 3094 3109
17. X. Ni, Y. Zhang, J. Ribas, W.H. Chowdhury, M. Castanares, Z. Zhang, M. Laiho, T.L. DeWeese, and S.E. Lupold Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts J. Clin. Invest. 121 2011 2383 2390
18. L.A. Wheeler, R. Trifonova, V. Vrbanac, E. Basar, S. McKernan, Z. Xu, E. Seung, M. Deruaz, T. Dudek, J.I. Einarsson, L. Yang, T.M. Allen, A.D. Luster, A.M. Tager, D.M. Dykxhoorn, and J. Lieberman Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras J. Clin. Invest. 121 2011 2401 2412
19. K.W. Thiel, L.I. Hernandez, J.P. Dassie, W.H. Thiel, X. Liu, K.R. Stockdale, A.M. Rothman, F.J. Hernandez, J.O. McNamara II, and P.H. Giangrande Delivery of chemo-sensitizing siRNAs to HER2 + - breast cancer cells using RNA aptamers Nucleic Acids Res. 40 2012 6319 6337
20. Q. Zhu, T. Shibata, T. Kabashima, and M. Kai Inhibition of HIV-1 protease expression in T cells owing to DNA aptamer-mediated specific delivery of siRNA Eur. J. Med. Chem. 56 2012 396 399
21. J. Zhou, C.P. Neff, P. Swiderski, H. Li, D.D. Smith, T. Aboellail, L. Remling-Mulder, R. Akkina, and J.J. Rossi Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge Mol. Ther. 21 2013 192 200
22. J.P. Dassie, and P.H. Giangrande Current progress on aptamer-targeted oligonucleotide therapeutics Ther. Deliv. 4 2013 1527 1546
23. C.L. Esposito, L. Cerchia, S. Catuogno, G. De Vita, J.P. Dassie, G. Santamaria, P. Swiderski, G. Condorelli, P.H. Giangrande, and V. de Franciscis Multifunctional aptamer-miRNA conjugates for targeted cancer therapy Mol. Ther. 22 2014 1151 1163
24. L. Cerchia, C.L. Esposito, S. Camorani, A. Rienzo, L. Stasio, L. Insabato, A. Affuso, and V. de Franciscis Targeting Axl with an high-affinity inhibitory aptamer Mol. Ther. 20 2012 2291 2303
25. S. Camorani, C.L. Esposito, A. Rienzo, S. Catuogno, M. Iaboni, G. Condorelli, V. de Franciscis, and L. Cerchia Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRβ aptamer Mol. Ther. 22 2014 828 841
26. M. Garofalo, C. Quintavalle, G. Romano, C.M. Croce, and G. Condorelli miR221/222 in cancer: their role in tumor progression and response to therapy Curr. Mol. Med. 12 2012 27 33
27. C. le Sage, R. Nagel, D.A. Egan, M. Schrier, E. Mesman, A. Mangiola, C. Anile, G. Maira, N. Mercatelli, S.A. Ciafrè, M.G. Farace, and R. Agami Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation EMBO J. 26 2007 3699 3708
28. M.R. Fabian, N. Sonenberg, and W. Filipowicz Regulation of mRNA translation and stability by microRNAs Annu. Rev. Biochem. 79 2010 351 379
29. P. Pineau, S. Volinia, K. McJunkin, A. Marchio, C. Battiston, B. Terris, V. Mazzaferro, S.W. Lowe, C.M. Croce, and A. Dejean miR-221 overexpression contributes to liver tumorigenesis Proc. Natl. Acad. Sci. U. S. A. 107 2010 264 269
30. C. Quintavalle, M. Garofalo, C. Zanca, G. Romano, M. Iaboni, M. del Basso De Caro, J.C. Martinez-Montero, M. Incoronato, G. Nuovo, C.M. Croce, and G. Condorelli miR-221/222 overexpression in human glioblastoma increases invasiveness by targeting the protein phosphate PTPμ Oncogene 31 2012 858 868
31. M. Karsy, E. Arslan, and F. Moy Current progress on understanding microRNAs in glioblastoma multiforme Genes Cancer 3 2012 3 15
32. L. Chen, J. Zhang, L. Han, A. Zhang, C. Zhang, Y. Zheng, T. Jiang, P. Pu, C. Jiang, and C. Kang Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status Oncol. Rep. 27 2012 854 860
33. G. Gabriely, M. Yi, R.S. Narayan, J.M. Niers, T. Wurdinger, J. Imitola, K.L. Ligon, S. Kesari, C. Esau, R.M. Stephens, B.A. Tannous, and A.M. Krichevsky Human glioma growth is controlled by microRNA-10b Cancer Res. 71 2011 3563 3572
34. W. Xiaoliang, L. Xuewen, K. Sanjay, Y.L. Chang, Z. Zhenfeng, and H. Balazs AXL kinase as a novel target for cancer therapy Oncotarget 5 2014 9546 9563
35. C.H. Heldin Targeting the PDGF signaling pathway in tumor treatment Cell Commun. Signal. 11 2013 97
36. C. Sun, and R. Bernards Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies Trends Biochem. Sci. 39 2014 465 474
37. A.L. Kasinski, K. Kelnar, C. Stahlhut, E. Orellana, J. Zhao, E. Shimer, S. Dysart, X. Chen, A.G. Bader, and F.J. Slack A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer Oncogene 2014 10.1038/onc.2014.282
38. M.S. Ebert, and P.A. Sharp MicroRNA sponges: progress and possibilities RNA 16 2010 2043 2050
39. F.C. Tay, J.K. Lim, H. Zhua, L.C. Hin, and S. Wang Using artificial microRNA sponges to achieve microRNA loss-of-function in cancer cells Adv. Drug Deliv. Rev. 81 C 2015 117 127
40. I.A. Babar, C.J. Cheng, C.J. Booth, X. Liang, J.B. Weidhaas, W.M. Saltzman, and F.J. Slack Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma Proc. Natl. Acad. Sci. U. S. A. 109 2012 1695 1704
41. M. Zhang, X. Zhou, B. Wang, B.C. Yung, L.J. Lee, K. Ghoshal, and R.J. Lee Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma J. Control. Release 168 2013 251 261